




The relative strengths and weaknesses of Bridgebio Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bridgebio Pharma Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 6.1% points. The greatest weakness of Bridgebio Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 163% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	888,858
Cost of Goods Sold	2,735
Intangible Assets	44,934
Liabilities, Current	135,069
Liabilities, Non-Current	470,249
Other Assets	48,934
Other Compr. Net Income	23,591
Other Expenses	379
Other Liabilities	1,273,053
Other Net Income	-9,822
Other Revenues	69,716
Property and Equipment	30,066
Research and Development	451,024
Selling, General and Administrative Expense	192,210

Output Variable	Value in 1000 USD
Assets	1,012,792
Liabilities	1,878,371
Expenses	646,348
Revenues	69,716
Stockholders Equity	-865,579
Net Income	-586,454
Comprehensive Net Income	-574,658
BaseVar	1,820,320
ECR before Limited Liability	-170%
Economic Capital Ratio	112%